BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16609064)

  • 21. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
    Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; Tefferi A
    Haematologica; 2006 Mar; 91(3):415-6. PubMed ID: 16531268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does anything work for anaemia in myelofibrosis?
    Birgegård G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):175-85. PubMed ID: 25189728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan.
    Shimoda K; Shide K; Kamezaki K; Okamura T; Harada N; Kinukawa N; Ohyashiki K; Niho Y; Mizoguchi H; Omine M; Ozawa K; Haradaa M
    Int J Hematol; 2007 May; 85(4):338-43. PubMed ID: 17483079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiosarcoma presenting with leucoerythroblastic anaemia bone marrow fibrosis and massive splenomegaly.
    Varma N; Vaiphei K; Varma S
    Br J Haematol; 2000 Sep; 110(3):503. PubMed ID: 10997958
    [No Abstract]   [Full Text] [Related]  

  • 25. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
    Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
    Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
    Arora B; Mesa R; Tefferi A
    Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
    Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
    Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
    Mesa RA; Quintás-Cardama A; Verstovsek S
    Curr Hematol Malig Rep; 2007 Feb; 2(1):25-33. PubMed ID: 20425385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension.
    Popat U; Frost A; Liu E; Guan Y; Durette A; Reddy V; Prchal JT
    Blood; 2006 May; 107(9):3486-8. PubMed ID: 16418333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
    Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
    Daver N; Cortes J; Newberry K; Jabbour E; Zhou L; Wang X; Pierce S; Kadia T; Sasaki K; Borthakur G; Ravandi F; Pemmaraju N; Kantarjian H; Verstovsek S
    Haematologica; 2015 Aug; 100(8):1058-63. PubMed ID: 26088933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
    Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
    Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
    Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of lenalidomide in myelodysplastic syndromes.
    List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
    N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
    Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
    Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
    Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
    Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
    J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.